Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions

01-2018: InflaRx to Present at Upcoming Investor Conferences

  • Home
  • Investors
  • Press Releases
  • Upcoming Investor Conferences

InflaRx to Present at Upcoming Investor Conferences

Jena, Germany, January 4, 2018 – InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, will present at the following conferences:


J.P. Morgan Annual Healthcare Conference

    Date: January 8-11, 2018,
    Presentation: Wed, 10th Jan 8:00 am PST  (5:00 pm CET)
    Venue: San Francisco, CA, USA
    Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx
    Arnd Christ, Chief Financial Officer of InflaRx

LEERINK Partners 7th Annual Global Healthcare Conference

    Date: February 14-15, 2018
    Presentation: Wed, 14th Feb 1:30 pm EST  (7:30 pm CET)
    Venue: New York, NY, USA
    Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx


Live webcasts of the presentations will be provided at www.InflaRx.com through the “Events & Presentations” section on the “Investors” page. A replay of the presentations will be available from InflaRx’s website following the conferences.


About InflaRx N.V.:

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the NASDAQ Global Select Market in the United States under the trading symbol “IFRX.”


Contacts:

InflaRx N.V.

Prof. Dr. Niels C. Riedemann - CEO
Email: info[at]inflarx.de
Tel: +49-3641-508180

 

MC Services AG

Katja Arnold, Andreas Jungfer
Email: inflarx[at]mc-services.eu
Tel: +49-89-210 2280

Download PDF

 image
Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V.
Winzerlaer Str. 2
07745 Jena

+49 (0)3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V.
Fraunhoferstraße 22
82152 Martinsried

+49 (0)89 414 189 78 00

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals